Indaptus TherapeuticsINDP
13F holders, Q3 2025 (September 30)5holders
2new positions
2sold out
$2.89avg. 13F price*
At the end of Q3 2025, 5 institutions reported holding Indaptus Therapeutics Inc. (INDP) in their 13F filings, unchanged from Q2 2025. 2 opened new positions and 2 sold out. The largest holders were Virtu Financial LLC ($55K), UBS Group AG ($1K) and Tower Research Capital LLC (TRC) ($1K).
- Company
- Indaptus Therapeutics Inc.
- CUSIP
- 45339J204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $56K |
| Exits | 2 | $126 |
All 13F filers, Q2 2025 → Q3 2025: 19,866 shares bought and 151 shares sold, net +19,715 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Virtu Financial LLC | 0.00% | New | 18,997 | $55K |
| UBS Group AG | 0.00% | New | 502 | $1K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +338.0% | 473 | $1K |
| Bank of America Corp. | 0.00% | Add +6.5% | 33 | $94 |
| SBI Securities Co., Ltd. | 0.00% | Reduce -89.1% | 17 | $49 |
"% of holder's portfolio" is INDP's weight in each manager's 13F, not the share of Indaptus Therapeutics Inc. the manager owns.